Trastuzumab
| Evidence Level: L1 | Predicted Indications: 10 |
Table of Contents
- Trastuzumab
- Trastuzumab: From HER2-Positive Breast Cancer to Progesterone-Receptor Positive Breast Cancer
Trastuzumab: From HER2-Positive Breast Cancer to Progesterone-Receptor Positive Breast Cancer
One-Sentence Summary
Trastuzumab is a HER2-targeted monoclonal antibody originally developed and approved for HER2-positive breast cancer (and later HER2-positive metastatic gastric cancer). The TxGNN model predicts it may also be effective for progesterone-receptor (PR) positive breast cancer, with 34 clinical trials and 20 publications currently identified in this evidence pack supporting this direction — most of which describe the HR+/HER2+ (“triple-positive”) molecular subgroup rather than a biologically new disease target.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | HER2-positive breast cancer (established indication; formal EMA label text not available in this evidence pack — see Data Gap DG001/DG002 below) |
| Predicted New Indication | Progesterone-Receptor Positive Breast Cancer |
| TxGNN Prediction Score | 99.90% |
| Evidence Level | L1 |
| EU Market Status | Not Marketed (per this evidence pack) |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Structured mechanism-of-action data was flagged as a data gap in this evidence pack (DG002, High severity). However, the underlying rationale captured alongside the prediction confirms the well-established pharmacology: trastuzumab is a humanized anti-HER2/ERBB2 monoclonal antibody that blocks HER2 dimerization signaling and mediates tumor cell killing through antibody-dependent cellular cytotoxicity (ADCC). This mechanism is the basis of its established use in HER2-overexpressing breast cancer.
Progesterone-receptor positive breast cancer frequently co-occurs with HER2 overexpression — this is the well-recognized “HR+/HER2+” (or “triple-positive” when ER is also positive) molecular subtype, which represents roughly 5–10% of all breast cancers. Importantly, this predicted indication is best understood as a molecular subgroup within the already-approved HER2-positive breast cancer indication, rather than an entirely novel disease category. PR positivity itself does not change the treatment decision — HER2 status (IHC3+ or FISH-amplified) remains the determining biomarker for anti-HER2 therapy eligibility, while PR status informs adjunctive endocrine therapy sequencing.
Mechanistically, this makes the prediction biologically coherent but clinically incremental: the evidence largely reflects combination strategies (trastuzumab plus aromatase inhibitors, fulvestrant, or CDK4/6 inhibitors) in patients who are already candidates for HER2-directed therapy under existing labeling, with PR status used to guide combination partner selection rather than trastuzumab eligibility itself.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01275677 | Phase 3 | Completed | 3,270 | Large adjuvant trial comparing chemotherapy alone vs. chemotherapy plus trastuzumab in node-positive/high-risk HER2-low invasive breast cancer, including HR+ subgroups. |
| NCT04629846 | Phase 3 | Completed | 517 | Randomized biosimilar equivalence trial of QL1209/pertuzumab plus trastuzumab and docetaxel in HER2+, ER/PR-negative early/locally advanced breast cancer, informing dosing/safety consistency across HR strata. |
| NCT00134680 | Phase 2 | Completed | 33 | Letrozole plus trastuzumab in ErbB2-positive and ER and/or PR-positive metastatic breast cancer — direct test of the trastuzumab + endocrine combination in this molecular subgroup. |
| NCT04886531 | Phase 2 | Recruiting | 30 | Neoadjuvant neratinib and endocrine therapy with trastuzumab in ER-positive, HER2-positive cancers. |
| NCT00005970 | Phase 3 | Completed | 3,436 | Landmark adjuvant trial of AC followed by weekly paclitaxel with or without trastuzumab in HER2-overexpressing node-positive/high-risk node-negative breast cancer. |
| NCT03726879 | Phase 3 | Completed | 454 | IMpassion050 — atezolizumab vs. placebo added to neoadjuvant chemotherapy plus trastuzumab/pertuzumab in early HER2-positive breast cancer. |
| NCT04420598 | Phase 2 | Completed | 41 | Trastuzumab deruxtecan in HER2+ advanced breast cancer with brain metastases and/or leptomeningeal carcinomatosis. |
| NCT02654119 | Phase 2 | Completed | 20 | Adjuvant cyclophosphamide/paclitaxel plus trastuzumab in stage I-II HER2/neu-positive breast cancer. |
| NCT00667251 | Phase 3 | Completed | 652 | Taxane-based chemotherapy with lapatinib vs. trastuzumab as first-line therapy in HER2/neu-positive metastatic breast cancer. |
| NCT00053339 | Phase 3 | Withdrawn | 0 | Trastuzumab with or without tamoxifen in ER/PR- and HER2/neu-positive stage IV breast cancer — directly targeted this subgroup but the trial was withdrawn before enrollment. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 32353342 | 2020 | RCT | The Lancet Oncology | monarcHER trial: abemaciclib plus trastuzumab ± fulvestrant vs. chemotherapy plus trastuzumab in HR+/HER2+ advanced breast cancer, showing improved progression-free survival with the chemo-free combination. |
| 26874901 | 2016 | RCT | The Lancet Oncology | ExteNET: neratinib after trastuzumab-based adjuvant therapy in HER2-positive early breast cancer, phase 3 placebo-controlled. |
| 28945833 | 2017 | RCT | Annals of Oncology | WSG-ADAPT HER2+/HR- trial: 12-week neoadjuvant dual HER2 blockade (trastuzumab + pertuzumab) ± paclitaxel, exploring chemotherapy de-escalation. |
| 37166817 | 2023 | RCT | JAMA Oncology | WSG-TP-II: endocrine therapy plus trastuzumab and pertuzumab vs. de-escalated chemotherapy in HR+/HER2+ early breast cancer — directly relevant to the PR/HR+ HER2+ subgroup. |
| 31410192 | 2019 | Cohort | Theranostics | Molecular portraits and trastuzumab responsiveness of ER-positive, PR-positive, and HER2-positive (“triple-positive”) breast cancer across a 32,056-patient SEER cohort. |
| 34983437 | 2022 | Retrospective | BMC Cancer | Trastuzumab plus fulvestrant combination therapy in HR-positive, HER2-positive advanced breast cancer — single-center efficacy data. |
| 38034484 | 2024 | Preclinical | Oncology Letters | Mechanistic study showing the inhibitory effect of trastuzumab on triple-positive BT474 breast cancer cells is reversed by combined progesterone and estradiol exposure — biological basis for PR-pathway crosstalk with HER2 blockade. |
| 27179402 | 2016 | RCT | The Lancet Oncology | NeoSphere 5-year analysis: neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer, reporting long-term progression-free/disease-free survival. |
| 26253814 | 2015 | Review | Breast (Edinburgh) | Review of the clinical implications of intrinsic molecular subtypes of breast cancer (Luminal A/B, HER2-enriched, Basal-like), framing HR/HER2 co-expression classification. |
| 39631485 | 2024 | Review | Pharmacological Research | Review of targeted and cytotoxic inhibitors used in breast cancer treatment, contextualizing trastuzumab within HER2/HR-status-driven treatment selection. |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (anti-HER2/ERBB2 monoclonal antibody; not a conventional cytotoxic chemotherapeutic) |
| Myelosuppression Risk | Low as monotherapy; risk rises substantially when combined with a cytotoxic chemotherapy backbone (e.g., taxane, anthracycline) |
| Emetogenicity Classification | Minimal to low |
| Monitoring Items | Cardiac function (baseline and periodic LVEF/echocardiogram — cardiotoxicity is the hallmark class-specific risk); CBC, liver and renal function when co-administered with cytotoxic chemotherapy |
| Handling Protection | Standard biologic infusion precautions (infusion-reaction monitoring); not classified as a cytotoxic hazardous drug requiring cytotoxic handling protocols, unlike conventional chemotherapy agents |
Safety Considerations
Please refer to the SmPC for safety information. Key warnings, contraindications, and drug interaction data were not available in this evidence pack (flagged as data gaps, see meta.data_gaps DG001/DG002).
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Multiple completed Phase 3 trials (e.g., NCT01275677, NCT04629846) and Phase 2/3 RCTs (e.g., monarcHER, WSG-TP-II, ExteNET) support the efficacy of trastuzumab in HR+/HER2+ breast cancer, meeting the L1 evidence bar. However, this predicted indication represents a molecular subgroup within the already-approved HER2-positive breast cancer indication rather than a wholly new disease target — PR positivity itself does not change eligibility, which remains defined by HER2 IHC3+/FISH-amplified status. Guardrails are needed to ensure patient selection is not driven by PR status alone.
To proceed, the following is needed:
- Resolve Blocking data gap DG001: obtain official product label warnings/contraindications (SmPC) for safety review (S1 gate)
- Resolve High-severity data gap DG002: obtain structured MOA and DrugBank classification data
- Confirm current EU marketing authorization status, since this evidence pack shows 0 active licenses / “Not Marketed”
- Clinical clarification on whether PR-positive status meaningfully changes treatment sequencing (e.g., endocrine partner selection) beyond the existing HER2-positive label
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.